GENK
GEN Restaurant Group, Inc.
GENK has slightly lower modeled downside risk, despite its lower overall score.
LCID
Lucid Group, Inc.
LCID has the edge over GENK overall, supported by stronger fundamentals and stronger modeled upside.
GENK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
GENK's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
GENK PE Valuation
GENK has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
GENK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect GENK's losses to shrink, with revenue holding steady.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
GENK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.89 | -$0.62 |
| Q2 2026 | -$0.84 | -$0.69 |
| Q1 2026 | -$0.75 | -$0.71 |
| Q4 2025 | -$0.59 | -554% |
| Q3 2025 | -$0.27 | -259% |
| Q2 2025 | -$0.15 | -163% |
| Q1 2025 | -$0.04 | -104% |
| Q4 2024 | $0.13 | -94% |
GENK lost $0.89 per share over the past year, and its loss has widened in each of the last 11 quarters.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID has the edge over GENK on earnings, with more consistent year-over-year improvement.
GENK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $48.7M | -3.3% |
| Q2 2026 | $55.7M | +1.2% |
| Q1 2026 | $53.9M | -6% |
| Q4 2025 | $49.7M | -9% |
| Q3 2025 | $50.4M | +2.7% |
| Q2 2025 | $55M | +2.2% |
| Q1 2025 | $57.3M | +13% |
| Q4 2024 | $54.7M | +21% |
GENK's revenue is shrinking: $49M last quarter, down 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -5 points |
| Q2 2026 | -9.2% | -5.8 points |
| Q1 2026 | -13% | -9.6 points |
| Q4 2025 | -25% | -22 points |
| Q3 2025 | -7.4% | -7.6 points |
| Q2 2025 | -3.4% | -6.4 points |
| Q1 2025 | -3.8% | -4 points |
| Q4 2024 | -2.4% | -0.4 points |
GENK has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over GENK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
GENK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.9M | +$767K |
| Q2 2026 | -$5.5M | +$835K |
| Q1 2026 | -$667K | +$4M |
| Q4 2025 | -$5.6M | -3516% |
| Q3 2025 | -$7.7M | -$870K |
| Q2 2025 | -$6.3M | -605% |
| Q1 2025 | -$4.7M | -$4.1M |
| Q4 2024 | $165K | -83% |
GENK has the edge over LCID on cash flow, with more consistent year-over-year improvement.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
GENK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +935K shares |
| 1 year | +20% | +1.1M shares |
| 3 years | +52% | +2.2M shares |
| 5 years | +75% | +2.7M shares |
GENK has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $1,000 |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $200,000 |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $320,000 |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
GENK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -0.7x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
| Q3 2024 | -2.1x | Net Cash |
| Q2 2024 | -2.4x | Net Cash |
| Q1 2024 | -2.0x | Net Cash |
| Q4 2023 | -1.8x | Net Cash |
| Q3 2023 | -1.6x | Net Cash |
GENK has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GENK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.8 | Oversold |
| Stochastic | 5.4 | Oversold |
GENK's weekly RSI is 26 (oversold) and its Stochastic is 5 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
GENK PE vs Consumer Cyclical Sector
| Metric | GENK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
GENK has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
GENK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.49 | 36% below |
| 20 week MA | $1.75 | 45% below |
| 50 week MA | $1.91 | 50% below |
| 100 week MA | $3.17 | 70% below |
LCID has stronger trend alignment. GENK is above 0 of 4 weekly averages versus LCID above 0 of 5.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
GENK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $17.0 | $7.83 | -54% |
| 2024 | $7.83 | $7.40 | -5.5% |
| 2025 | $7.40 | $2.41 | -67% |
| 2026 YTD | $2.41 | $0.96 | -60% |
GENK has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.